Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies

References

• Lazar A, Evans H, Shipley J. Leiomyosarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PC, Mertens F, editors. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon, France: IARC Press, 2013; p. 111–13.
   Google Scholar
• ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102–12. doi:10.1093/annonc/mdu254. PMID:25210080
   PubMed Web of Science ®Google Scholar
• Duffaud F, Ray-Coquard I, Salas S, Pautier P. Recent advances in understanding and managing leiomyosarcomas. F1000prime Rep. 2015;7:55. doi:10.12703/P7-55. PMID:26097728
   PubMedGoogle Scholar
• Penel N, Italiano A, Isambert N, Bompas E, Bousquet G, Duffaud F, French Sarcoma Group. (Groupe Sarcome Français/Groupe d'Etude des Tumeurs Osseuses). Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy. Ann Oncol. 2010;21(6):1361–5. doi:10.1093/annonc/mdp485. PMID:19880438
   PubMed Web of Science ®Google Scholar
• Nabeshima A, Matsumoto Y, Fukushi J, Iura K, Matsunobu T, Endo M, Fujiwara T, Iida K, Fujiwara Y, Hatano M, et al. Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3 K/Akt pathways. Br J Cancer. 2015;112(3):547–55. doi:10.1038/bjc.2014.637. PMID:25562433
   PubMed Web of Science ®Google Scholar
• Buddingh EP, Kuijjer ML, Duim RAJ, Bürger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PCW, Lankester AC, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: A rationale for treatment with macrophage activating agents. Clin Cancer Res. 2011;17(8):2110–9. doi:10.1158/1078-0432.CCR-10-2047. PMID:21372215
   PubMed Web of Science ®Google Scholar
• van Dongen M, Savage NDL, Jordanova ES, Briaire-de Bruijn IH, Walburg KV, Ottenhoff THM, Hogendoorn PCW, van der Burg SH, Gelderblom H, van Hall T. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer. 2010;127(4):899–909. PMID:20013807
   PubMed Web of Science ®Google Scholar
• Lee C-H, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N, Nielsen TO, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 2008;14(5):1423–30. doi:10.1158/1078-0432.CCR-07-1712. PMID:18316565
   PubMed Web of Science ®Google Scholar
• Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013;35(5):585–600. doi:10.1007/s00281-013-0367-7. PMID:23657835
   PubMed Web of Science ®Google Scholar
• Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651–62. doi:10.1016/S1470-2045(16)00078-4. PMID:27055731
   PubMed Web of Science ®Google Scholar
• Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846–59. doi:10.1016/j.ccr.2014.05.016. PMID:24898549
   PubMed Web of Science ®Google Scholar
• Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med. 2015;373(5):428–37. doi:10.1056/NEJMoa1411366. PMID:26222558
   PubMed Web of Science ®Google Scholar
• Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg A-M, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: A dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16(8):949–56. doi:10.1016/S1470-2045(15)00132-1. PMID:26179200
   PubMed Web of Science ®Google Scholar
• Lim J, Poulin NM, Nielsen TO. New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype. Clin Cancer Res. 2015;21(21):4753–9. doi:10.1158/1078-0432.CCR-15-0831. PMID:26330427
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8. doi:10.1126/science.aaa1348. PMID:25765070
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71. doi:10.1038/nature13954. PMID:25428505
   PubMed Web of Science ®Google Scholar
• Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin K-H, Hu H, Kim KS, Choi YD, Kim S, et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer. 2016;16:434. doi:10.1186/s12885-016-2451-6. PMID:27393385
   PubMed Web of Science ®Google Scholar
• D'Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin L-X, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46(3):357–65. doi:10.1016/j.humpath.2014.11.001. PMID:25540867
   PubMed Web of Science ®Google Scholar
• Paydas S, Bagir EK, Deveci MA, Gonlusen G. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol. 2016;33(8):93. doi:10.1007/s12032-016-0807-z. PMID:27421997
   PubMed Web of Science ®Google Scholar
• Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PloS One. 2013;8(12):e82870. doi:10.1371/journal.pone.0082870. PMID:24349382
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen L. Classification of advanced human cancers based on tumor immunity in the microEnvironment (TIME) for cancer immunotherapy. JAMA Oncol. 2016;2(11):1403–4. doi:10.1001/jamaoncol.2016.2450. PMID:27490017
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: From mechanisms to therapy. Immunity. 2014;41(1):49–61. doi:10.1016/j.immuni.2014.06.010. PMID:25035953
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–96. doi:10.1038/ni.1937. PMID:20856220
   PubMed Web of Science ®Google Scholar
• Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51. doi:10.1016/j.cell.2010.03.014. PMID:20371344
   PubMed Web of Science ®Google Scholar
• Cleton-Jansen A-M, Buddingh EP, Lankester AC. Immunotherapy: Is it different for sarcomas? Oncoimmunology. 2012;1(2):255–7. doi:10.4161/onci.1.2.18345. PMID:22720262
   PubMed Web of Science ®Google Scholar
• Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, et al. Macrophage activation and polarization: Nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20. doi:10.1016/j.immuni.2014.06.008. PMID:25035950
   PubMed Web of Science ®Google Scholar
• Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004;64(19):7022–9. doi:10.1158/0008-5472.CAN-04-1449. PMID:15466195
   PubMed Web of Science ®Google Scholar
• Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008;320(5877):807–11. doi:10.1126/science.1154370. PMID:18467591
   PubMed Web of Science ®Google Scholar
• Foucher ED, Blanchard S, Preisser L, Garo E, Ifrah N, Guardiola P, Delneste Y, Jeannin P. IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. Antagonistic effects of GM-CSF and IFNγ. PloS One. 2013;8(2):e56045. doi:10.1371/journal.pone.0056045. PMID:23409120
   PubMed Web of Science ®Google Scholar
• Espinosa I, Beck AH, Lee C-H, Zhu S, Montgomery KD, Marinelli RJ, Ganjoo KN, Nielsen TO, Gilks CB, West RB, et al. Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol. 2009;174(6):2347–56. doi:10.2353/ajpath.2009.081037. PMID:19443701
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. doi:10.1038/nrc3239. PMID:22437870
   PubMed Web of Science ®Google Scholar
• Appleyard ST, Dunn MJ, Dubowitz V, Rose ML. Increased expression of HLA ABC class I antigens by muscle fibres in duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders. Lancet. 1985;1(8425):361–3. doi:10.1016/S0140-6736(85)91384-4. PMID:2857418
   PubMed Web of Science ®Google Scholar
• Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103. doi:10.1038/bjc.2011.189. PMID:21629244
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, Guo Z, Peng G, Chen G, He J, et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine. 2015;94(6):e515. doi:10.1097/MD.0000000000000515. PMID:25674748
   PubMed Web of Science ®Google Scholar
• Budczies J, Mechtersheimer G, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, Endris V, Lier A, et al. PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. Oncoimmunology. 2017;6(3):e1279777. doi:10.1080/2162402X.2017.1279777. PMID:28405504
   PubMed Web of Science ®Google Scholar
• Burgess M, Bolejack V, Van Tine B, Schuetze S, Hu J, D'Angelo S, Attia S, Priebat D, Okuno S, Riedel RF, et al. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. J Clin Oncol. 2017;35 No 15_suppl:11008–11008.
   Web of Science ®Google Scholar
• Ben-Ami E, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Severgnini M, Patel T, et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer. 2017;123(17):3285–3290. doi:10.1002/cncr.30738.
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Cacavio A, Ghesani M, Karambelkar A, Rapkiewicz A, Weber J, Rosen G. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6:24. doi:10.1186/s13569-016-0064-0. PMID:28042471
   PubMed Web of Science ®Google Scholar
• Heine A, Kristiansen G, Schild HH, Brossart P. Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab. Ann Oncol. 2016;27(9):1813–4. doi:10.1093/annonc/mdw243. PMID:27329248
   PubMed Web of Science ®Google Scholar
• Wolchock JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall Survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Toulmonde M, Penel N, Adam J, Chevreau C, Blay J-Y, Le Cesne A, Bompas E, Piperno-Neumann S, Cousin S, Grellety T, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: A phase 2 clinical trial. JAMA Oncol. 2017; doi:10.1001/jamaoncol.2017.1617. PMID:28662235
   PubMed Web of Science ®Google Scholar
• Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, Goussot JF, David M, Bonichon F, Lagarde C. Soft-tissue sarcomas of adults; Study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33(1):37–42. doi:10.1002/ijc.2910330108. PMID:6693192
   PubMed Web of Science ®Google Scholar
• Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med. 2011;9:216. doi:10.1186/1479-5876-9-216. PMID:22176642
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu L, Gong C, Shi H, Zeng Y, Wang X, Zhao Y, Wei Y. Prognostic significance of tumor-associated macrophages in solid tumor: A meta-analysis of the literature. PloS One. 2012;7(12):e50946. doi:10.1371/journal.pone.0050946. PMID:23284651
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13. doi:10.1056/NEJMoa020177. PMID:12529460
   PubMed Web of Science ®Google Scholar
• Kostine M, Cleven AH, de Miranda NF, Italiano A, Cleton-Jansen AM, Bovée JV. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol. 2016;29(9):1028–37.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. doi:10.1056/NEJMoa1501824. PMID:27312065.
   PubMed Web of Science ®Google Scholar
• de Vrij J, Maas SLN, Kwappenberg KMC, Schnoor R, Kleijn A, Dekker L, Luider TM, de Witte LD, Litjens M, van Strien ME, et al. Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells. Int J Cancer. 2015;137(7):1630–42. doi:10.1002/ijc.29521. PMID:25802036
   PubMed Web of Science ®Google Scholar